Precipio Inc
precipiodx.comPrecipio Inc (NASDAQ: PRPO) is a healthcare biotechnology company that focuses on improving cancer diagnostics, with an emphasis on hematologic malignancies. The company generates revenue through two integrated divisions: a pathology services division that performs clinical laboratory testing, and a products division that develops and sells proprietary diagnostic assays and kits to other clinical laboratories. The pathology services division operates fully equipped clinical laboratories staffed with specialized personnel, while the products division targets broader market reach by enabling third-party labs to perform testing using Precipio's proprietary tools. The integrated structure treats the clinical laboratory operation as a self-funded R&D unit, using patient specimens and clinical workflows to develop and validate diagnostic products. Precipio does not pay cash dividends on its common stock as of its FY2025 10-K filed March 30, 2026, and the company has disclosed a history of insufficient capital resources to pay obligations on a timely basis.
Products & Services
Pathology services including complex diagnostic testing for hematologic malignancies; proprietary diagnostic assays and kits designed for use by external clinical laboratories to improve testing accessibility and laboratory workflow efficiency.
Revenue Model
Revenue comes from two streams: fee-for-service clinical laboratory testing (pathology services division, reimbursed by insurance payers and other payors) and product sales of proprietary diagnostic assays and kits to third-party clinical laboratories (products division). No segment revenue percentages are disclosed in the available filing excerpts.
Customers & Markets
End markets include clinical laboratories, healthcare providers, and patients requiring cancer diagnostics, with a focus on hematologic malignancies. Reimbursement is tied to insurance payers and government health programs. No specific customer concentration data is disclosed in the available filing excerpts.
Geographic Exposure
Primarily U.S.-based operations. The filing references compliance obligations under GDPR and UK data protection laws, indicating some exposure to or consideration of UK and EEA markets, but primary operations are domestic. No specific international revenue breakdown is disclosed in the available filing excerpts.
Financial Snapshot
Loading...
